{"id":"https://openalex.org/W4281789620","doi":"https://doi.org/10.2337/db22-213-or","title":"213-OR: Antidiabetic Potential of Novel, Long-Acting Amylin Analogue ZP8396 in ZDF Rats","display_name":"213-OR: Antidiabetic Potential of Novel, Long-Acting Amylin Analogue ZP8396 in ZDF Rats","publication_year":2022,"publication_date":"2022-05-31","ids":{"openalex":"https://openalex.org/W4281789620","doi":"https://doi.org/10.2337/db22-213-or"},"language":"en","primary_location":{"id":"doi:10.2337/db22-213-or","doi":"https://doi.org/10.2337/db22-213-or","is_oa":false,"landing_page_url":"https://doi.org/10.2337/db22-213-or","pdf_url":null,"source":{"id":"https://openalex.org/S129060628","display_name":"Diabetes","issn_l":"0012-1797","issn":["0012-1797","1939-327X"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320274","host_organization_name":"American Diabetes Association","host_organization_lineage":["https://openalex.org/P4310320274"],"host_organization_lineage_names":["American Diabetes Association"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Diabetes","raw_type":"journal-article"},"volume":null,"type":"article","is_traditional":true,"indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5014807421","display_name":"Jolanta Skarbaliene","orcid":"https://orcid.org/0000-0003-3965-7504","observed_orcids":["https://orcid.org/0000-0003-3965-7504"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"JOLANTA SKARBALIENE","raw_affiliation_strings":["S\u00f8borg, Copenhagen, Denmark, Biberach an der Riss, Germany"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"S\u00f8borg, Copenhagen, Denmark, Biberach an der Riss, Germany","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5010246793","display_name":"Tamara Baader-Pagler","orcid":"https://orcid.org/0000-0002-1672-8739","observed_orcids":["https://orcid.org/0000-0002-1672-8739"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"TAMARA BAADER-PAGLER","raw_affiliation_strings":["S\u00f8borg, Copenhagen, Denmark, Biberach an der Riss, Germany"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"S\u00f8borg, Copenhagen, Denmark, Biberach an der Riss, Germany","institution_ids":[]}]},{"author_position":"last","author":{"id":null,"display_name":"PER-OLOF ERIKSSON","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"PER-OLOF ERIKSSON","raw_affiliation_strings":["S\u00f8borg, Copenhagen, Denmark, Biberach an der Riss, Germany"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"S\u00f8borg, Copenhagen, Denmark, Biberach an der Riss, Germany","institution_ids":[]}]}],"institutions":[],"countries_distinct_count":0,"institutions_distinct_count":0,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":0.0,"has_fulltext":false,"cited_by_count":0,"citation_normalized_percentile":{"value":0.0,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":null,"biblio":{"volume":"71","issue":"Supplement_1","first_page":null,"last_page":null},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10401","display_name":"Diabetes Treatment and Management","score":0.9955999851226807,"subfield":{"id":"https://openalex.org/subfields/2712","display_name":"Endocrinology, Diabetes and Metabolism"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10401","display_name":"Diabetes Treatment and Management","score":0.9955999851226807,"subfield":{"id":"https://openalex.org/subfields/2712","display_name":"Endocrinology, Diabetes and Metabolism"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10839","display_name":"Pancreatic function and diabetes","score":0.0008999999845400453,"subfield":{"id":"https://openalex.org/subfields/2712","display_name":"Endocrinology, Diabetes and Metabolism"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10560","display_name":"Diabetes Management and Research","score":0.0007999999797903001,"subfield":{"id":"https://openalex.org/subfields/2712","display_name":"Endocrinology, Diabetes and Metabolism"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/amylin-analogues","display_name":"amylin analogues","score":0.8970000147819519},{"id":"https://openalex.org/keywords/type-2-diabetes","display_name":"type 2 diabetes","score":0.875},{"id":"https://openalex.org/keywords/antidiabetic-potential","display_name":"antidiabetic potential","score":0.7929999828338623},{"id":"https://openalex.org/keywords/blood-glucose","display_name":"blood glucose","score":0.578000009059906},{"id":"https://openalex.org/keywords/plasma-glucagon","display_name":"plasma glucagon","score":0.9100000262260437},{"id":"https://openalex.org/keywords/weight-loss","display_name":"weight loss","score":0.9100000262260437},{"id":"https://openalex.org/keywords/zucker-diabetic-fatty-rats","display_name":"Zucker diabetic fatty rats","score":0.7120000123977661},{"id":"https://openalex.org/keywords/glucose-homeostasis","display_name":"glucose homeostasis","score":0.7540000081062317},{"id":"https://openalex.org/keywords/pramlintide","display_name":"pramlintide","score":0.828000009059906},{"id":"https://openalex.org/keywords/semaglutide","display_name":"semaglutide","score":0.9150000214576721},{"id":"https://openalex.org/keywords/glp-1-receptor-agonists","display_name":"GLP-1 receptor agonists","score":0.8159999847412109}],"concepts":[{"id":"https://openalex.org/C2780705028","wikidata":"https://www.wikidata.org/wiki/Q424643","display_name":"Amylin","level":4,"score":0.9311466217041016},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.8109040856361389},{"id":"https://openalex.org/C134018914","wikidata":"https://www.wikidata.org/wiki/Q162606","display_name":"Endocrinology","level":1,"score":0.7781761884689331},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.7063261270523071},{"id":"https://openalex.org/C2780533449","wikidata":"https://www.wikidata.org/wiki/Q417762","display_name":"Exenatide","level":4,"score":0.6665811538696289},{"id":"https://openalex.org/C2778199505","wikidata":"https://www.wikidata.org/wiki/Q2992990","display_name":"Postprandial","level":3,"score":0.6503657698631287},{"id":"https://openalex.org/C544821477","wikidata":"https://www.wikidata.org/wiki/Q718113","display_name":"Weight loss","level":3,"score":0.5492711663246155},{"id":"https://openalex.org/C3020479747","wikidata":"https://www.wikidata.org/wiki/Q1029907","display_name":"Gastric emptying","level":3,"score":0.5386917591094971},{"id":"https://openalex.org/C555293320","wikidata":"https://www.wikidata.org/wiki/Q12206","display_name":"Diabetes mellitus","level":2,"score":0.5249985456466675},{"id":"https://openalex.org/C3018667095","wikidata":"https://www.wikidata.org/wiki/Q3455903","display_name":"Glucose homeostasis","level":4,"score":0.47747373580932617},{"id":"https://openalex.org/C2778563252","wikidata":"https://www.wikidata.org/wiki/Q170617","display_name":"Glucagon","level":3,"score":0.4754359722137451},{"id":"https://openalex.org/C2780473172","wikidata":"https://www.wikidata.org/wiki/Q5572518","display_name":"Glycemic","level":3,"score":0.4662059545516968},{"id":"https://openalex.org/C2776390293","wikidata":"https://www.wikidata.org/wiki/Q2035485","display_name":"Subcutaneous injection","level":2,"score":0.41127967834472656},{"id":"https://openalex.org/C2779306644","wikidata":"https://www.wikidata.org/wiki/Q2002370","display_name":"Insulin","level":2,"score":0.38493698835372925},{"id":"https://openalex.org/C2777180221","wikidata":"https://www.wikidata.org/wiki/Q3025883","display_name":"Type 2 diabetes","level":3,"score":0.36020922660827637},{"id":"https://openalex.org/C511355011","wikidata":"https://www.wikidata.org/wiki/Q12174","display_name":"Obesity","level":2,"score":0.2072412073612213},{"id":"https://openalex.org/C2777391703","wikidata":"https://www.wikidata.org/wiki/Q1053470","display_name":"Insulin resistance","level":3,"score":0.20615339279174805},{"id":"https://openalex.org/C2779422922","wikidata":"https://www.wikidata.org/wiki/Q1029907","display_name":"Stomach","level":2,"score":0.08187329769134521},{"id":"https://openalex.org/C165220095","wikidata":"https://www.wikidata.org/wiki/Q207524","display_name":"Islet","level":3,"score":0.0}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.2337/db22-213-or","doi":"https://doi.org/10.2337/db22-213-or","is_oa":false,"landing_page_url":"https://doi.org/10.2337/db22-213-or","pdf_url":null,"source":{"id":"https://openalex.org/S129060628","display_name":"Diabetes","issn_l":"0012-1797","issn":["0012-1797","1939-327X"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320274","host_organization_name":"American Diabetes Association","host_organization_lineage":["https://openalex.org/P4310320274"],"host_organization_lineage_names":["American Diabetes Association"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Diabetes","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"display_name":"Good health and well-being","score":0.9763000011444092,"id":"https://metadata.un.org/sdg/3"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W4281786876","https://openalex.org/W4381378349","https://openalex.org/W7163635109","https://openalex.org/W2936463866","https://openalex.org/W2623643363","https://openalex.org/W4206996811","https://openalex.org/W7098709916","https://openalex.org/W7131280588","https://openalex.org/W2165885047","https://openalex.org/W4412059548"],"abstract_inverted_index":{"Amylin":[0],"improves":[1],"glucose":[2,203,216],"homeostasis":[3],"through":[4],"at":[5,205,247],"least":[6],"three":[7],"distinct":[8],"mechanisms":[9],"of":[10,14,22,107,124,142,181,195,280,284],"action,":[11],"including":[12],"prevention":[13],"the":[15,104,182,281],"postprandial":[16],"rise":[17],"in":[18,49,81,86,109,131,160,169,174,201,214,240,256],"plasma":[19,233],"glucagon,":[20],"slowing":[21],"gastric":[23],"emptying,":[24],"and":[25,33,64,85,146,184,222],"increased":[26],"satiety,":[27],"leading":[28],"to":[29,60,186,274],"decreased":[30],"caloric":[31],"intake":[32],"potential":[34,106,117],"weight":[35,79,158,171],"loss.":[36],"Clinical":[37],"efficacy":[38],"has":[39],"been":[40],"demonstrated":[41],"with":[42,68,88,177,287],"short-acting":[43],"amylin":[44,57,266],"analogue":[45,58],"pramlintide.":[46],"ZP8396,":[47],"currently":[48],"phase":[50],"1":[51],"clinical":[52],"testing,":[53],"is":[54,289],"a":[55,90,119,155,198,210,237],"long-acting,":[56],"designed":[59],"improve":[61],"solubility,":[62],"stability":[63],"allow":[65],"for":[66,149],"co-formulation":[67],"other":[69],"relevant":[70],"peptides.":[71],"We":[72],"previously":[73],"reported":[74],"that":[75,264],"ZP8396":[76,108,125,178,196,230,259,288],"provides":[77],"body":[78,157,170],"reduction":[80,200],"DIO":[82],"rats":[83,133,162,175,243],"alone":[84],"combination":[87],"semaglutide,":[89],"once-weekly":[91],"GLP-1":[92],"agonist":[93],"(Skarbaliene":[94],"et":[95],"al,":[96],"Obesity":[97],"Week":[98],"2021)":[99],".":[100,228,253],"Here":[101],"we":[102],"investigated":[103],"antidiabetes":[105,116,282],"Zucker":[110],"Diabetic":[111],"Fatty":[112],"(ZDF)":[113],"rats.":[114],"The":[115],"after":[118,152],"single":[120,192],"subcutaneous":[121],"(s.c.)":[122],"injection":[123,194],"(nmol/kg)":[126],"or":[127],"vehicle":[128,164,219,245],"was":[129,172],"measured":[130],"ZDF":[132,161],"(aged":[134],"12-13":[135],"weeks,":[136],"n=10)":[137],",":[138],"an":[139],"animal":[140],"model":[141],"type":[143],"2":[144],"diabetes,":[145],"continuously":[147],"monitored":[148],"168":[150],"h":[151,188,207,249],"dosing.ZP8396":[153],"induced":[154],"significant":[156,167,199],"loss":[159],"vs.":[163,218,244],"group.":[165],"A":[166],"decrease":[168],"observed":[173],"treated":[176],"from":[179],"initiation":[180],"dosing":[183],"up":[185],"96":[187],"post-dose.":[189],"In":[190,254],"addition,":[191],"s.c.":[193],"showed":[197],"blood":[202,215],"levels":[204,217],"24":[206,248],"post-dose,":[208],"reaching":[209,236],"20":[211],"%":[212],"difference":[213,239],"group":[220,246],"(14,97\u00b10,39":[221],"18,60\u00b11,18":[223],"mmol/L,":[224],"respectively;":[225],"p":[226],"<0.05)":[227,252],"Also,":[229],"significantly":[231],"reduced":[232],"glucagon":[234],"levels,":[235],"55%":[238],"ZP8396-treated":[241],"diabetic":[242,257],"post-dose":[250],"(p":[251],"conclusion,":[255],"rat":[258],"improved":[260],"glycaemic":[261],"status,":[262],"supporting":[263],"long-acting":[265],"analogues":[267],"may":[268],"provide":[269],"future":[270],"valuable":[271],"therapeutic":[272],"options":[273],"manage":[275],"diabetes.":[276],"Further":[277],"preclinical":[278],"characterization":[279],"effects":[283],"long-term":[285],"treatment":[286],"ongoing.":[290],"Disclosure":[291],"J.Skarbaliene:":[292],"Employee;":[293,302,308],"Zealand":[294,298,309],"Pharma":[295,299,310],"A/S,":[296],"Stock/Shareholder;":[297],"A/S.":[300,311],"T.Baader-pagler:":[301],"Boehringer":[303],"Ingelheim":[304],"International":[305],"GmbH.":[306],"P.Eriksson:":[307]},"counts_by_year":[],"updated_date":"2026-10-12T09:40:04.860316","created_date":"2022-06-13T00:00:00"}